# A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer

> **NCT06962787** · PHASE2 · RECRUITING · sponsor: **Sichuan Baili Pharmaceutical Co., Ltd.** · enrollment: 260 (estimated)

## Conditions studied

- Renal Cancer

## Interventions

- **DRUG:** BL-B01D1
- **DRUG:** Axitinib
- **DRUG:** Lenvatinib
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT06962787
- **Lead sponsor:** Sichuan Baili Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-28
- **Primary completion:** 2027-05
- **Final completion:** 2027-12
- **Target enrollment:** 260 (ESTIMATED)
- **Last updated:** 2025-11-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06962787

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06962787, "A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06962787. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*